Life Sciences & Biotechnology
Title : | Exosomes as therapeutic drug carriers and delivery vehicle development for import substitution |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Biotechnology, Pharmacology |
Principal Investigator : | Dr. Indrani Datta, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengalore, Karnataka (560029) |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | indranidatta.nimhans@gmail.com,mahadevananita@gmail.com |
Details
Executive Summary : | The study aims to develop exosomes of mesenchymal stromal cells (MSCs) as a therapeutic drug carrier and delivery vehicle for Parkinson's disease. The primary objectives include isolating and characterizing exosomes from human adult tissue dental pulp derived MSCs, loading exosomes with phloroglucinol and oleuropein, and biodistributing exo-phloroglucinol and exo-oleuropein in an MPTP in vivo PD model. The study also aims to evaluate the efficacy of exo-phloroglucinol and exo-oleuropein in Parkinson's disease patient iPSC-derived dopaminergic neurons at the single-cell level in vitro. The study also aims to validate the exosomes' drug-action on pre-clinical PD models and patient iPSC-derived DA-neuronal-cell models. Exosomes can deliver biological cargo, including mRNAs, miRNAs, drugs, and proteins. This project aims to develop MSC-derived exosomes for drug delivery targeting antioxidant effects and alpha-synuclein de-aggregation in the midbrain. The study will use high-end NIR technology to estimate exosomes' biodistribution in organs and assess their impact on behavioral parameters. The exosomes will be tested using human PD-patient iPSC-derived DA-neurons, providing competitive solutions for drug delivery in the midbrain. |
Co-PI: | Prof. Anita Mahadevan, National Institute Of Mental Health And Neurosciences (NIMHANS), Bengalore, Karnataka (560029) |
Total Budget (INR): | 38,03,880 |
Organizations involved